Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial

Journal:

Nature Communications

Published:

2026-01-07

DOI:

10.1038/s41467-025-68165-7

Affiliations:

21

Authors:

34

Go to article

Institutions	Authors	Share
Sciwind Biosciences Co., Ltd., China	13.000000 13.000000	0.38
Drum Tower Hospital, China	3.000000	0.09
Nanjing First Hospital, China	1.000000	0.03
People’s Hospital of Liaoning Province, China	1.000000	0.03
China Rehabilitation Research Center (CRRC), China	1.000000	0.03
The First Affiliated Hospital of Soochow University, China	1.000000	0.03
Jinan Central Hospital, China	1.000000	0.03
The Affiliated Jiangning Hospital, Nanjing Medical University, China	1.000000	0.03
First Affiliated Hospital of Nanyang Medical College, China	1.000000	0.03
The First People Hospital of Yueyang, China	1.000000	0.03
The First Affiliated Hospital of Henan University of Science and Technology, China	1.000000	0.03
Daqing People's Hospital, China	1.000000	0.03
Second Affiliated Hospital of Nanjing Medical University, China	1.000000	0.03
Third Hospital of Changsha, China	1.000000	0.03
The Second People's Hospital of Yibin, China	1.000000	0.03
Second Affiliated Hospital, AHMU, China	1.000000	0.03
Affiliated Hospital of SDMPU, China	1.000000	0.03
CNPC Central Hospital, China	1.000000	0.03
Shiyan Renmin Hospital, China	1.000000	0.03
Sciwind Biosciences, USA, United States of America (USA)	1.000000	0.03

Interested in Clinical Sciences?